See more : COPAM – Companhia Portuguesa de Amidos, S.A. (CPA.LS) Income Statement Analysis – Financial Results
Complete financial analysis of Fusen Pharmaceutical Company Limited (1652.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Fusen Pharmaceutical Company Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Ni Steel Co.,Ltd (008260.KS) Income Statement Analysis – Financial Results
- Gemina Laboratories Ltd. (GLAB.CN) Income Statement Analysis – Financial Results
- Tiemco Ltd. (TIEMF) Income Statement Analysis – Financial Results
- Goodbaby International Holdings Limited (1086.HK) Income Statement Analysis – Financial Results
- 8VI Holdings Limited (8VI.AX) Income Statement Analysis – Financial Results
Fusen Pharmaceutical Company Limited (1652.HK)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.fusenyy.com
About Fusen Pharmaceutical Company Limited
Fusen Pharmaceutical Company Limited, an investment holding company, manufactures and sells pharmaceutical products in the People's Republic of China. The company's product portfolio includes Shuanghuanglian-based cold medicines comprising Shuanghuanglian oral solutions and Shuanghuanglian injections; and flunarizine hydrochloride capsules and compound ferrous sulfate granules, as well as Yuanhu Zhitong oral solutions, Ganweikang tablets, and Yixinkang tablets. In addition, it researches, develops, produces, and sells various proprietary Chinese medicines and western medicine products for the treatment of cold and fever, cardiovascular diseases, and anemia. Further, the company offers business management and consulting services. Fusen Pharmaceutical Company Limited was founded in 2003 and is headquartered in Nanyang, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 565.61M | 491.76M | 385.66M | 486.85M | 407.39M | 462.06M | 452.58M | 441.99M | 368.63M |
| Cost of Revenue | 266.10M | 266.74M | 174.53M | 220.79M | 194.90M | 210.74M | 200.63M | 219.80M | 195.36M |
| Gross Profit | 299.51M | 225.02M | 211.13M | 266.07M | 212.49M | 251.32M | 251.95M | 222.19M | 173.28M |
| Gross Profit Ratio | 52.95% | 45.76% | 54.75% | 54.65% | 52.16% | 54.39% | 55.67% | 50.27% | 47.01% |
| Research & Development | 80.98M | 15.38M | 10.64M | 27.28M | 11.61M | 11.22M | 3.36M | 701.00K | 325.00K |
| General & Administrative | 74.90M | 69.92M | 65.24M | 78.87M | 58.73M | 49.30M | 44.98M | 40.28M | 26.04M |
| Selling & Marketing | 139.54M | 118.72M | 90.95M | 107.41M | 112.81M | 89.59M | 90.70M | 74.21M | 63.64M |
| SG&A | 214.44M | 188.64M | 156.18M | 186.28M | 171.53M | 138.89M | 135.68M | 114.49M | 89.68M |
| Other Expenses | -15.93M | -2.23M | -9.54M | -4.45M | -5.43M | 983.00K | 710.00K | 2.54M | 1.95M |
| Operating Expenses | 279.49M | 186.41M | 146.65M | 181.83M | 166.11M | 127.71M | 130.48M | 106.13M | 88.38M |
| Cost & Expenses | 545.59M | 453.15M | 321.18M | 402.62M | 361.01M | 338.45M | 331.11M | 325.93M | 283.74M |
| Interest Income | 424.00K | 1.97M | 2.56M | 1.43M | 3.66M | 2.41M | 22.77M | 36.13M | 38.16M |
| Interest Expense | 12.58M | 12.38M | 8.24M | 9.43M | 9.19M | 15.60M | 28.61M | 39.61M | 42.39M |
| Depreciation & Amortization | 35.80M | 34.16M | 23.79M | 22.46M | 21.23M | 16.81M | 16.20M | 15.25M | 15.06M |
| EBITDA | 18.93M | 49.90M | 86.84M | 110.30M | 75.35M | 144.75M | 138.38M | 169.62M | 101.92M |
| EBITDA Ratio | 3.35% | 10.15% | 22.52% | 25.81% | 18.50% | 31.33% | 35.60% | 38.38% | 31.12% |
| Operating Income | 20.02M | 15.74M | 52.14M | 103.22M | 66.15M | 136.07M | 122.18M | 118.59M | 86.85M |
| Operating Income Ratio | 3.54% | 3.20% | 13.52% | 21.20% | 16.24% | 29.45% | 27.00% | 26.83% | 23.56% |
| Total Other Income/Expenses | -49.46M | -74.75M | -28.35M | -24.81M | -2.33M | -12.25M | -5.84M | -3.82M | -29.59M |
| Income Before Tax | -29.45M | -30.99M | 23.79M | 78.41M | 63.81M | 123.81M | 116.34M | 114.77M | 57.27M |
| Income Before Tax Ratio | -5.21% | -6.30% | 6.17% | 16.10% | 15.66% | 26.80% | 25.71% | 25.97% | 15.54% |
| Income Tax Expense | 6.85M | 3.66M | 7.18M | 15.74M | 11.56M | 21.91M | 19.29M | 18.57M | 11.23M |
| Net Income | -36.28M | -34.65M | 16.65M | 70.13M | 53.43M | 101.88M | 96.82M | 95.07M | 44.88M |
| Net Income Ratio | -6.41% | -7.05% | 4.32% | 14.40% | 13.12% | 22.05% | 21.39% | 21.51% | 12.17% |
| EPS | -0.05 | -0.05 | 0.02 | 0.09 | 0.07 | 0.15 | 0.12 | 0.12 | 0.06 |
| EPS Diluted | -0.05 | -0.05 | 0.02 | 0.09 | 0.07 | 0.15 | 0.12 | 0.12 | 0.06 |
| Weighted Avg Shares Out | 725.54M | 756.07M | 769.62M | 786.08M | 800.00M | 694.80M | 800.00M | 800.00M | 800.00M |
| Weighted Avg Shares Out (Dil) | 752.06M | 756.07M | 770.31M | 790.16M | 802.95M | 694.80M | 800.00M | 800.00M | 800.00M |
Source: https://incomestatements.info
Category: Stock Reports